UK – Janssen disappointed with second NICE no for Spravato

Janssen says it is disappointed with second draft guidance from the National Institute for Health and Care Excellence (NICE) rejecting NHS funds for its nasal depression spray Spravato (esketamine).

Following a second appraisal consultation, the Institute is not recommending use of the spray, in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI), for adults living with treatment-resistant major depressive disorder (MDD) who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode.

According to NICE, clinical trials suggest that Spravato with an SSRI or SNRI may be more effective than placebo with an SSRI or SNRI, but it is unclear how effective Spravato is “because of the way the trials were done”…